Milton, Daniel T <br/><br/>
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.  [electronic resource] 

 -  Cancer  Sep 2006 
 - 1034-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.22088  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease Progression<br/>ErbB Receptors--genetics<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Survival Rate